Recent studies have explored innovative approaches to improve treatment outcomes for patients with liver-related cancers, demonstrating the potential of both pharmacological interventions and advanced predictive models. One study delves into the benefits of statin use post-hepatic resection in patients with hepatocellular carcinoma (HCC), uncovering that statin users experience notably better recurrence-free survival (RFS) and overall survival (OS) rates. This research, grounded in a comprehensive analysis of data from a nationwide cohort in Korea, also identifies a duration-response relationship between statin use and improved prognosis, particularly highlighting the significant advantages for non-cirrhotic patients, those with larger tumors, or those exhibiting early HCC recurrence. In parallel, another investigation introduces a novel multi-modal deep learning model, DERBY and its enhanced version DERBY+, designed to predict the efficacy of bevacizumab treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM). By integrating data from PET/CT images, clinical records, and colonoscopy biopsy specimens, the DERBY+ model, especially, shows high accuracy in forecasting treatment response, suggesting a pathway towards personalized medicine. Both studies underscore the importance of leveraging diverse data sources and innovative technologies to refine treatment strategies for liver cancer, aiming to significantly improve patient outcomes through tailored therapeutic approaches.